SEC Form 4 · accession 0001209191-18-028394
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Gonella
Director
Period of report
May 3, 2018
Accepted (ET)
May 7, 2018 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 3, 2018 | M | 30,000 | $0.85 | A | 12,086,413 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.85 | May 3, 2018 | M | 30,000 | D | — | May 13, 2018 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The options vested and became exercisable in four equal quarterly installments following the grant date of May 14, 2008, and had an expiration date of May 13, 2018.